• Kyverna Therapeutics completed its miv-cel biologics license application for stiff person syndrome in the fourth quarter of 2026, seeking priority review.
• A potential US launch is targeted for 2027, with pricing expected at a significant premium to oncology CAR T therapies’ $500,000-$600,000.
• One-year trial data showed a 49% median reduction in timed walking duration; 92% of patients remained off chronic immunotherapies for SPS.
• Cash and securities totaled $170.6 million at September 30, 2026; operating runway, including loan availability, extends into 2028.
• Phase 3 enrollment in generalized myasthenia gravis is expected to finish in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.